| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $486,137 ) |
| | 2025 | 2025 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R01AI173567 | Assays for acceleration: from fit-for-purpose models to scalable assays of broad systemic and mucosal protection against all strains of Group A Streptococcus | 000 | 3 | NIH | 12/20/2024 | $486,137 |
|
| Issue Date FY: 2024 ( Subtotal = $606,985 ) |
| | 2024 | 2024 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R21AI179004 | Understanding the effects of Gender Affirming Hormone Therapy (GAHT) on immune function using a systems immunology approach | 001 | 2 | NIH | 8/16/2024 | $120,516 |
| | 2024 | 2024 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R21AI179004 | Understanding the effects of Gender Affirming Hormone Therapy (GAHT) on immune function using a systems immunology approach | 001 | 2 | NIH | 8/16/2024 | -$120,516 |
| | 2024 | 2024 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R21AI179004 | Understanding the effects of Gender Affirming Hormone Therapy (GAHT) on immune function using a systems immunology approach | 000 | 2 | NIH | 8/2/2024 | $120,516 |
| | 2024 | 2024 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R01AI173567 | Assays for acceleration: from fit-for-purpose models to scalable assays of broad systemic and mucosal protection against all strains of Group A Streptococcus | 000 | 2 | NIH | 11/29/2023 | $437,822 |
| | 2024 | 2024 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R01AI173567 | Assays for acceleration: from fit-for-purpose models to scalable assays of broad systemic and mucosal protection against all strains of Group A Streptococcus | 001 | 2 | NIH | 4/16/2024 | $48,647 |
|
| Issue Date FY: 2023 ( Subtotal = $623,632 ) |
| | 2023 | 2023 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R21AI179004 | Understanding the effects of Gender Affirming Hormone Therapy (GAHT) on immune function using a systems immunology approach | 000 | 1 | NIH | 8/22/2023 | $151,363 |
| | 2023 | 2023 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | | | | AUS | R01AI173567 | Assays for acceleration: from fit-for-purpose models to scalable assays of broad systemic and mucosal protection against all strains of Group A Streptococcus | 000 | 1 | NIH | 12/30/2022 | $472,269 |
|
| Issue Date FY: 2021 ( Subtotal = -$9,517 ) |
| | 2021 | 2019 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | NULL | | | AUS | UH3DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 5 | NIH | 2/17/2021 | -$9,517 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | | 3052 | | AUS | UH3DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 5 | NIH | 7/14/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $345,722 ) |
| | 2019 | 2019 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | | 3052 | | AUS | UH3DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 5 | NIH | 8/8/2019 | $345,722 |
|
| Issue Date FY: 2018 ( Subtotal = $346,000 ) |
| | 2018 | 2018 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | | 3052 | | AUS | UH3DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 001 | 4 | NIH | 9/5/2018 | $346,000 |
| | 2018 | 2017 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | | 3052 | | AUS | UH3DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 3 | NIH | 1/24/2018 | $9,694 |
| | 2018 | 2016 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | | 3052 | | AUS | UH2DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 2 | NIH | 1/24/2018 | -$9,694 |
|
| Issue Date FY: 2017 ( Subtotal = $346,000 ) |
| | 2017 | 2017 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDRENS HOSPITAL FLEMINGTON RD | PARKVILLE | | 3052 | | AUS | UH3DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 3 | NIH | 9/12/2017 | $346,000 |
|
| Issue Date FY: 2016 ( Subtotal = $345,777 ) |
| | 2016 | 2016 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDREN S HOSPITAL | PARKVILLE, VICTORIA | | | | AUS | UH2DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 2 | NIH | 9/13/2016 | $345,777 |
|
| Issue Date FY: 2015 ( Subtotal = $345,600 ) |
| | 2015 | 2015 | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDREN S HOSPITAL | PARKVILLE, VICTORIA | | | | AUS | UH2DK107344 | Generating kidney organoids and mature renal cell types via directed iPSC differentiation | 000 | 1 | NIH | 9/23/2015 | $345,600 |
|
| Issue Date FY: 2011 ( Subtotal = $444,018 ) |
| | 2011 | 2011 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | Flemington Road | Parkville | | | | AUS | R01AI085198 | THE SAFETY OF PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CHILDREN - A FOLLOWUP STUDY. | 000 | 2 | NIH | 7/27/2011 | $444,018 |
| | 2011 | 2010 | MCRI ROYAL CHILDRENS HOSPITAL | FLEMINGTON ROAD | PARKVILLE | | | | AUS | R01AI085198 | THE SAFETY OF PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CHILDREN - A FOLLOWUP STUDY. | 001 | 1 | NIH | 8/25/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $491,637 ) |
| | 2010 | 2010 | MURDOCH CHILDREN'S RESEARCH INSTITUTE | Flemington Road | Parkville | | | | AUS | R01AI085198 | THE SAFETY OF PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CHILDREN - A FOLLOWUP STUDY. | 000 | 1 | NIH | 8/2/2010 | $491,637 |
|
|
